Navigation Links
MicroRNA undermines tumor suppression
Date:3/17/2009

FINDINGS: Scientists at the Whitehead Institute for Biomedical Research and the National University of Singapore have discovered the first microRNA (miRNA) capable of directly tamping down the activity of the well known tumor-suppressor gene, p53, While p53 functions to prevent tumor formation, the p53 gene is thought to malfunction in more than 50% of cancerous tumors.

RELEVANCE: The study reports the first time a miRNA has been shown to directly affect the p53 protein level, although researchers have previously identified other genes and miRNAs that indirectly affect p53's activity.

CAMBRIDGE, Mass. (March 17, 2009) A small piece of RNA, or microRNA (miRNA), ratchets down the activity of the tumor-suppressor gene p53, according to a study by Whitehead Institute and National University of Singapore researchers.

While p53 functions to suppress tumor formation, the p53 gene is thought to malfunction in more than 50% of cancerous tumors.

The study published online March 17 in Genes and Development reports the first time that a miRNA has been shown to directly affect the p53 gene, although researchers have previously identified other genes and miRNAs that regulate p53's activity indirectly.

"For critical genes like p53, it's important that they are maintained at the right level in the cell," says Beiyan Zhou, a postdoctoral researcher in the lab of Whitehead Member Harvey Lodish and mentor to the paper's first author, Minh Le. "Le's work describes one more layer of regulatory mechanism that balances p53 gene expression."

miRNAs, short snippets of RNA, usually reduce how often a certain gene is translated into a protein. When a miRNA matches with and binds to a given messenger RNA coding for a specific protein, thereby preventing that messenger RNA from acting as a template for protein creation.

To investigate whether any miRNAs directly affect p53, Le, who is a joint graduate student in Lodish's lab and in the lab of Bing Lim at the National University of Singapore, searched the p53 gene for any sites that matched with known miRNAs from two databases. Only miRNA125b potentially has p53 target sites in humans, in zebrafish, and in many other vertebrates, indicating that it was important enough in cellular processes to be conserved through evolution.

Le tested miRNA125b's effects on several types of cells known to express p53, including human neural and lung cells. When Le reduced the amount of miRNA125b in the cells, p53 levels and the number of cells undergoing apoptosis (a type of programmed cell death that can be triggered by p53) both increased, whereas an increase in miRNA125b levels decreased levels of p53 and the number of apoptotic cells.

To confirm that miRNA125b played a similar role in developing organisms, Le changed the miRNA125b levels in zebrafish embryos. When she reduced miRNA125b levels in the embryos, cellular p53 levels and apoptosis both increased.

"Taking all of this data together, the p53 pathway is a major target of miRNA125b," says Lodish, who is also a professor of biology and bioengineering at MIT. "Most miRNAs have multiple targets, but there are a few cases that a miRNA has one major target and this is one of them."


'/>"/>

Contact: Nicole Giese
giese@wi.mit.edu
617-258-6851
Whitehead Institute for Biomedical Research
Source:Eurekalert

Related medicine news :

1. MicroRNAs make for safer cancer treatments
2. Gladstone scientists identify single microRNA that controls blood vessel development
3. Putting microRNAs on the stem cell map
4. Need microRNA processing? Get Smad
5. MicroRNA controls expression of oncogenes
6. MicroRNAs appear essential for retinal health
7. MicroRNAs, EMT and cancer progression
8. Replacing absent microRNAs could make tumors less invasive, more treatable
9. Single microRNA fine-tunes innate immune response
10. MicroRNAs May Predict Colon Cancer Prognosis
11. 2 microRNAs promote spread of tumor cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... , ... July 26, 2017 , ... Team Type 1 ... to medicine for everyone affected by diabetes, is excited to announce the 106 college ... Ambassador Program. , Established in 2005, the Team Type 1 Foundation has bestowed ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... dogs and cats has opened in Jupiter. The state of the art ... and class leading treatments with a goal of providing heart patients longer lives. ...
(Date:7/26/2017)... ... 2017 , ... Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) ... development of pharmaceutical and consumer products, announces the operational numbers of its wholly-owned ... International LLC recorded unaudited fiscal Q1 profits of $897,596 based on revenues of ...
(Date:7/26/2017)... ... 2017 , ... Wendy M. Musielak, a partner at the Andrew Cores Family Law ... Association’s third Vice President earlier this year. She will serve the membership in this capacity ... President, in accordance with the organization’s by-laws. , Musielak joined the Andrew ...
(Date:7/26/2017)... ... July 26, 2017 , ... The number of adults 65 years or ... ways to improve asthma control in the population are not well described. In a ... Practice), an official journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... EXTON, Pa., July 27, 2017  West Pharmaceutical Services, ... financial results for the second-quarter 2017 and updated financial ... Second-Quarter 2017 Highlights Reported ... 2.5% over the prior-year quarter. Net sales at constant ... 2017 reported-diluted EPS was $0.51, compared to $0.60 in ...
(Date:7/25/2017)... BARCELONA, Spain and CAMBRIDGE, Massachusetts ... SOM Biotech, specializing in repurposing drugs to treat rare nervous ... Therapeutics Inc. to clinically develop and market the drug SOM0226 ... reached, the drug achieved very promising results in a Phase ... A new office in the United ...
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July 21, 2017 ... ) announced today that it will report its second ... Thursday, July 27, 2017. ... July 27, 2017, at 9:00 a.m. Eastern Time.  The ... dialing 1-970-315-0533.  A rebroadcast of the teleconference will be ...
Breaking Medicine Technology: